America and Britain Reach Duty-Free Agreement on Drugs.
The United Kingdom and the United States have signed a major bilateral deal that will preserve no tariffs on UK medicine shipments going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This move secures that import taxes on these crucial exports will stay at zero for a timeframe of three years.
This agreement is in response to previous warnings to hike tariffs on branded drug products, with increases mentioned reaching double the cost.
"This deal with the UK strengthens the global environment for cutting-edge drugs and establishes long-overdue equity to American-British medicine commerce," a release declared.
Trade Importance
Medicines constitute one of the UK's biggest goods shipped to the US, which is by far the primary destination for major companies like GSK and AstraZeneca.
Trade data show that in the year leading up to September, the UK sold medicines worth ÂŁ11.1bn to the US. This amount represented 17.4% of total UK exports in that span.
"This agreement protects employment, boosts investment and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The deal entails several notable changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be restricted at fifteen percent. Last year, rebates were more than 20%.
Recent Tensions
The pact follows a protracted row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
The disagreement were intensified by claims that US customers were charged a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been pledged toward American operations.
One official acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
